DCPH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (11 Jun 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.08% compare to its pairs and should correct upwards.

Stats
今日成交量	1.57M
平均成交量	2.04M
市值	2.21B
EPS	$-0.520 ( Q1 \| 2024-05-10 )
下一个收益日期	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.58 (Sector) 42.63 (Industry) 0
ATR14	$0.00600 (0.02%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Brightstar Associates Llc	Buy	48 136	Common Stock
2024-04-22	Brightstar Associates Llc	Sell	48 136	Warrants (right to buy)
2024-02-15	Sherman Matthew L	Buy	17 275	Common Stock
2024-02-16	Sherman Matthew L	Sell	2 615	Common Stock
2024-02-15	Sherman Matthew L	Buy	69 100	Stock Option (Right to Buy)

INSIDER POWER
30.99
Last 99 transactions
Buy: 7 012 970 \| Sell: 3 558 980

相关性 (AI algo v.1.1b): Undervalued: 0.08% $25.63 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.56 (weak)

短: 0.95 (very strong)

Signal:(68.551) Expect same movement, but be aware

Deciphera Pharmaceuticals 相关性

10 最正相关
OZEM	1
AGBA	0.95
THCP	0.909
POET	0.893
NTIC	0.888
HIBB	0.874
UAL	0.872
STCN	0.869
NBBK	0.868
HLP	0.857

10 最负相关
RFAIU	-0.958
ICLK	-0.943
INDH	-0.921
VAXX	-0.9
IIMFX	-0.876
CETX	-0.869
ERNZ	-0.856
IBAC	-0.855
GLYC	-0.85
GRDI	-0.848

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Deciphera Pharmaceuticals 相关性 - 货币/商品

0.02
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.30
( neutral )

Deciphera Pharmaceuticals 财务报表

Annual	2023
营收:	$163.36M
毛利润:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2023
营收:	$163.36M
毛利润:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2022
营收:	$134.04M
毛利润:	$125.27M (93.46 %)
EPS:	$-2.37

FY	2021
营收:	$96.15M
毛利润:	$93.22M (96.95 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Deciphera Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.